Castle Biosciences (CSTL) Operating Leases (2021 - 2026)

Castle Biosciences (CSTL) has 6 years of Operating Leases data on file, last reported at $25.1 million in Q1 2026.

• Quarterly Operating Leases rose 78.77% year-over-year to $25.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.1 million (up 78.77% YoY) and the FY2025 annual result came in at $25.2 million, up 75.79% from the prior year.
• Operating Leases was little changed at $25.1 million in Q1 2026 per CSTL's latest filing, from $25.2 million in the prior quarter.
• The five-year high for Operating Leases was $25.4 million in Q2 2025, with the low at $6.5 million in Q2 2022.
• Average Operating Leases over 5 years is $15.3 million, with a median of $13.9 million recorded in 2024.
• Year-over-year, Operating Leases surged 91.77% in 2023 and grew 1.21% in 2024.
• Castle Biosciences' Operating Leases stood at $11.5 million in 2022, then climbed by 22.89% to $14.2 million in 2023, then gained by 1.21% to $14.3 million in 2024, then jumped by 75.79% to $25.2 million in 2025, then declined by 0.4% to $25.1 million in 2026.
• Business Quant data shows CSTL's Operating Leases at $25.1 million in Q1 2026, $25.2 million in Q4 2025, and $25.3 million in Q3 2025.